You are here

Press Release Archive

- Pfizer Animal Health Medicine Used to Treat Whales

(BUSINESS WIRE)--Responding to a request from the Marine Mammal Center, Pfizer Animal Health (PAH) has donated an antibiotic which was used today to treat the two humpback whales lost and injured in the Sacramento River. "We hope mother and baby recover and find their way home," said Christina Dougherty, VMD, Senior Veterinarian, Pfizer Animal Health. Pfizer veterinarians have been working with veterinarians from the Marine

- Pfizer Supports Complete Smoking Ban in Public Areas and Improved Access to Smoking Cessation Treatments across Europe

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) (LSE:PFZ) welcomes the European Commission’s Green Paper on smoke free environments1, which was put for public consultation earlier this year. Today in Brussels, a week before World No Tobacco Day (May 31st), the world’s leading life sciences company submitted its recommendations on the questions raised in the Commission’s Paper. The Consultation will conclude on June 1st

- Pfizer Says Research and Development Head John LaMattina Will Retire This Year

(BUSINESS WIRE)--Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company’s research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and outside the company for his successor, and Dr. LaMattina has agreed to remain during this period to ensure a smoot

- Pharmacia and Upjohn Will Appeal Verdict in Simon Case, 'Ruling is Not Supported by the Evidence'

(BUSINESS WIRE)--Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle Simon’s breast cancer. The case, Simon vs. Wyeth, et al., was heard in the Philadelphia Court of Common Pleas. “While we have great sympathy for what Mrs. Simon and her family have been through, today’s verdict is neither supported by the evidence introduced

- Counterfeit Drugs Put Lives at Risk

(BUSINESS WIRE)--Pfizer welcomes the 1st European Parliamentary symposium on pharmaceuticals “Putting an end to drug counter-feiting”, which convened European policy makers, regulators and specialists on counterfeiting and medicines trading in the European Parliament today. “Pfizer is very concerned about the surges in counterfeit medicines, putting at risk the lives and wellbeing of patients inmore

- Pfizer Invites Public to Listen to Webcast of July 18 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Wednesday, July 18. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web site

- Pfizer Launches Online Initiative Disclosing Its U.S. Post-Marketing Commitments

(BUSINESS WIRE)--Pfizer announced today that it has launched an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments. Post-marketing commitments are studies conducted after a medicine receives regulatory approval, often as a requirement for approval or continued marketing of some medicines. The studies are designed to provide additional information about the medicine’s safety

- Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to study results presented today at the American Academy of Neurology annual meeting. Clinically, this outcome would equate to a patient with severe pain reporting a reduction to mild to moderate pain. Fibromyalgia is one of the most common chronic, widespread pain conditions and is

- Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014

(BUSINESS WIRE)--Pfizer Inc reported today that the Federal Court of Appeal of Canada has reversed a lower court ruling that would have permitted generic manufacturer Novopharm to launch a competitor product to Celebrex. The appellate court issued an order prohibiting regulatory approval of Novopharm’s product in Canada until Celebrex’s compound patent expires in November 2014. “Today’s ruling is an

- Pfizer Foundation's ConnectHIV Initiative Provides $7.5 Million in Grants to Community-Based AIDS Service Organizations Across 10 States

(BUSINESS WIRE)--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the Foundation’s latest initiative to support organizations working to stop the spread and impact of HIV/AIDS. ConnectHIV integrates lessons learned from the Southern HIV/AIDS Prevention Initiative, the Foundation’s recently completed 3-year prevention initiative to

- Pfizer Invites Public to View and/or Listen to Webcasts of Pfizer Participation at Healthcare Conferences

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Vice Chairman David Shedlarz at the 32nd Annual Deutsche Bank Health Care Conference on Wednesday, May 2, at 11:15 a.m. Eastern Daylight Savings Time, and to listen to a webcast of participation by Vice Chairman David Shedlarz and other Pfizer executives in a discussion at the Morgan Stanley Global Healthcare Unplugged

- Pfizer Declares a 29-cent Second-Quarter, 2007, Dividend

(BUSINESS WIRE) The board of directors of Pfizer Inc today declared a 29-cent second-quarter, 2007, dividend on the company's common stock, payable June 5, 2007, to shareholders of record on May 11, 2007. Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The second-quarter 2007 cash dividend will be the 274th

- Pfizer Focused on Delivering the Value Customers Expect and Shareholders Deserve, CEO Kindler Tells Shareholders

(BUSINESS WIRE)--In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler said, “We’re operating in an incredibly dynamic industry environment – one that, day in and day out, presents us with a whole range of promising opportunities. To succeed in this environment, we must fundamentally change the way we’ve done business in the past – and eventually

- FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted unanimously (12-0) to recommend the approval of maraviroc, a CCR5 antagonist, for use along with other antiretroviral agents for treatment-experienced patients infected with CCR5-tropic HIV-1. If approved, maraviroc would be the first member of a new class of oral HIV medicines in more than a

- Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full-Year Expectations for 2007 and 2008


Pfizer: ($ billions, except per-share amounts) First Quarter 2007 2006 Revenues $12.474 $11.747 Reported Net Income

- Pfizer Invites Public to Access Webcast of April 26 Annual Meeting of Shareholders

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 26. To access the Webcast, visit our Website at and click on the “Webcast of the Annual Meeting” link under the “Annual Meeting of Shareholders” section. Pre-registration for the Webcast will be available at that linkmore

- Pfizer Invites Public to Listen to Webcast of April 20 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web site homepage

- Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer

(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges stemming from the off-label marketing of Genotropin — a human growth hormone medicine — and the inappropriate use of a vendor contract to increase the sales of other Pharmacia medicines. Both settlements cover activities that occurred at Pharmacia before that

- Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

(BUSINESS WIRE) Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by significantly reducing the risk of cardiovascular events in patients with heart disease, according to two separate economic analyses. The data were presented at the annual meeting of the American College of Cardiology. “One of these analyses suggests that even with the availability of low


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.